↓ Skip to main content

Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

Overview of attention for article published in Drug Resistance Updates, July 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
32 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Published in
Drug Resistance Updates, July 2015
DOI 10.1016/j.drup.2015.06.001
Pubmed ID
Authors

Selvaraju, Karthik, Mazurkiewicz, Magdalena, Wang, Xin, Gullbo, Joachim, Linder, Stig, D'Arcy, Pádraig

Abstract

Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival. The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target. However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting. Recently the deubiquitinases (DUBs), a diverse family of enzymes that catalyze ubiquitin removal, have attracted significant interest as targets for the development of next generation UPS inhibitors. In particular, pharmacological inhibition of the proteasomal cysteine DUBs (i.e., USP14 and UCHL5) has been shown to be particularly cytotoxic to cancer cells and inhibit tumour growth in several in vivo models. In the current review we focus on the modes of action of proteasome DUB inhibitors and discus the potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 5 16%
Student > Ph. D. Student 5 16%
Student > Master 4 13%
Student > Bachelor 4 13%
Researcher 4 13%
Other 10 31%
Readers by discipline Count As %
Agricultural and Biological Sciences 13 41%
Biochemistry, Genetics and Molecular Biology 7 22%
Unspecified 5 16%
Medicine and Dentistry 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 3 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2015.
All research outputs
#2,891,243
of 5,441,501 outputs
Outputs from Drug Resistance Updates
#37
of 72 outputs
Outputs of similar age
#103,444
of 189,877 outputs
Outputs of similar age from Drug Resistance Updates
#5
of 6 outputs
Altmetric has tracked 5,441,501 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 72 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,877 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.